Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on toll-like receptor 4

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1477-1487

  Schelbergen, Rik F P ^a   Blom, Arjen B ^a   Van Den Bosch, Martijn H J ^a   Slöetjes, Annet ^a   Abdollahi Roodsaz, Shahla ^a   Schreurs, B Wim ^a   Mort, John S ^b   Vogl, Thomas ^c   Roth, Johannes ^c   Van Den Berg, Wim B ^a   Van Lent, Peter L E M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AGGRECAN; CALGRANULIN A; CALGRANULIN B; COLLAGEN TYPE 2; COLLAGENASE 3; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEOGLYCAN; STROMELYSIN; TOLL LIKE RECEPTOR 4;

ARTICLE; BIOSYNTHESIS; CARTILAGE CELL; CARTILAGE MATRIX; CATABOLISM; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

BIOLOGICAL MARKERS; CALGRANULIN A; CALGRANULIN B; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CYTOKINES; EPITOPES; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; MATRIX METALLOPROTEINASES; OLIGOPEPTIDES; OSTEOARTHRITIS; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84858962775     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33495     Document Type: Article

References (46)

1. Goldring MB, Goldring SR,. Osteoarthritis. J Cell Physiol 2007; 213: 626-34.
2. Van den Berg WB,. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 2011; 19: 338-41.
3. Sellam J, Berenbaum F,. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010; 6: 625-35.
4. Attur M, Samuels J, Krasnokutsky S, Abramson SB,. Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence? Best Pract Res Clin Rheumatol 2010; 24: 71-9.
5. Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M,. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritisâresults of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005; 13: 361-7.
6. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H,. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
7. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB,. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis [review]. Arthritis Rheum 2010; 62: 647-57.
8. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H, et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor κB and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R69.
9. Oppenheim JJ, Yang D,. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005; 17: 359-65.
10. Foell D, Wittkowski H, Vogl T, Roth J,. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
11. Marenholz I, Heizmann CW, Fritz G,. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-22.
12. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C,. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 9496-502.
13. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
14. Van Lent PL, Grevers LC, Blom AB, Arntz OJ, van de Loo FA, van der Kraan P, et al. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum 2008; 58: 3776-87.
15. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-43.
16. Hammer HB, Odegard S, Syversen SW, Landewe R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 150-4.
17. Foell D, Roth J,. Proinflammatory S100 proteins in arthritis and autoimmune disease [review]. Arthritis Rheum 2004; 50: 3762-71.
18. Brun JG, Jonsson R, Haga HJ,. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994; 21: 733-8.
19. Van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008; 67: 1750-8.
20. Zreiqat H, Belluoccio D, Smith MM, Wilson R, Rowley LA, Jones K, et al. S100A8 and S100A9 in experimental osteoarthritis. Arthritis Res Ther 2010; 12: R16.
21. Vogl T, Roth J, Sorg C, Hillenkamp F, Strupat K,. Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 detected by ultraviolet matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom 1999; 10: 1124-30.
22. Vogl T, Leukert N, Barczyk K, Strupat K, Roth J,. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim Biophys Acta 2006; 1763: 1298-306.
23. Ii M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006; 69: 1288-95.
24. Srikrishna G, Toomre DK, Manzi A, Panneerselvam K, Freeze HH, Varki A, et al. A novel anionic modification of N-glycans on mammalian endothelial cells is recognized by activated neutrophils and modulates acute inflammatory responses. J Immunol 2001; 166: 624-32.
25. Van Lent PL, van den Berg WB, Schalkwijk J, van de Putte LB, van den Bersselaar L,. The impact of protein size and charge on its retention in articular cartilage. J Rheumatol 1987; 14: 798-805.
26. Martel-Pelletier J, Boileau C, Pelletier JP, Roughley PJ,. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008; 22: 351-84.
27. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R,. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol 2005; 175: 8296-302.
28. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J,. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86: 557-66.
29. Gebhardt C, Nemeth J, Angel P, Hess J,. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72: 1622-31.
30. Abramson SB, Attur M,. Developments in the scientific understanding of osteoarthritis. Arthritis Res Ther 2009; 11: 227.
31. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M,. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24: 365-71.
32. Furuzawa-Carballeda J, Macip-Rodriguez PM, Cabral AR,. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response. Clin Exp Rheumatol 2008; 26: 554-60.
33. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B,. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-7.
34. Farahat MN, Yanni G, Poston R, Panayi GS,. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993; 52: 870-5.
35. Merz D, Liu R, Johnson K, Terkeltaub R,. IL-8/CXCL8 and growth-related oncogene α/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 2003; 171: 4406-15.
36. Van Lent PL, Blom AB, Schelbergen RF, Sloetjes A, Lafeber FP, Lems WF, et al. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum 2012; 64: 1466-76.
37. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 2006; 5: 6.
38. Van Lent PL, Grevers LC, Schelbergen R, Blom A, Geurts J, Sloetjes A, et al. S100A8 causes a shift toward expression of activatory Fcγ receptors on macrophages via Toll-like receptor 4 and regulates Fcγ receptor expression in synovium during chronic experimental arthritis. Arthritis Rheum 2010; 62: 3353-64.
39. Miranda KJ, Loeser RF, Yammani RR,. Sumoylation and nuclear translocation of S100A4 regulate IL-1β-mediated production of matrix metalloproteinase-13. J Biol Chem 2010; 285: 31517-24.
40. Cecil DL, Terkeltaub R,. Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol 2008; 180: 8378-85.
41. Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, et al. Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of Toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum 2007; 56: 1880-93.
42. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008; 83: 1484-92.
43. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR,. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008; 102: 1239-46.
44. Yammani RR, Carlson CS, Bresnick AR, Loeser RF,. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 2006; 54: 2901-11.
45. Srikrishna G, Panneerselvam K, Westphal V, Abraham V, Varki A, Freeze HH,. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. J Immunol 2001; 166: 4678-88.
46. Zhang Q, Hui W, Litherland GJ, Barter MJ, Davidson R, Darrah C, et al. Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 2008; 67: 1633-41.